Brief: Poxel: More Positive Phase 2A Results, Phase 2B Plan For Pxl770 In NASH

Poxel SA

14/12/2020 07:22

Dec 14 (Reuters) - Poxel SA  POXEL.PA :
    * POXEL ANNOUNCES ADDITIONAL POSITIVE PHASE 2A RESULTS, AND
PHASE
2B PLAN FOR PXL770, AN ORAL FIRST-IN-CLASS AMPK ACTIVATOR, IN
NASH
    * NEW RESULTS FROM PHASE 2A STAMP-NAFLD TRIAL SHOW
CONSISTENTLY
GREATER RESPONSE IN HIGH-RISK PATIENTS WITH COEXISTING TYPE 2
DIABETES (T2DM), ESTIMATED TO BE APPROXIMATELY 50% OF NASH
PATIENTS
    * CLINICALLY MEANINGFUL IMPROVEMENTS (P<0.05) IN LIVER FAT
CONTENT, LIVER ENZYMES ALANINE TRANSAMINASE (ALT) AND ASPARTATE
TRANSAMINASE (AST), FASTING GLUCOSE AND HEMOGLOBIN A1C (HBA1C)
WERE OBSERVED IN PXL770-TREATED PATIENTS WITH T2DM
    * NEW PRECLINICAL RESULTS DEMONSTRATED PXL770 PRODUCED
DIRECT
BENEFICIAL EFFECTS ON HUMAN CELLS WHICH MEDIATE FIBROSIS
(STELLATE CELLS) AND INFLAMMATION (MACROPHAGES)
    * PLANS TO CONDUCT A 52-WEEK PHASE 2B TRIAL EVALUATING UP TO
TWO
DOSES OF PXL770 IN UP TO 120 PATIENTS PER STUDY ARM WITH
BIOPSY-PROVEN NASH AND PRE-DIABETES OR T2DM

Source text for Eikon:  ID:nBwbSqW2da 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))